Cbr Systems
Part of Generate Life Sciences
Is this your company?
Cbr Systems Snapshot
Our mission is to help find therapies for conditions that have no cure today. We are working to advance the real-life applications of newborn stem cells by funding clinical trials.
Advancing Medicine
A pioneer in newborn stem cell collection and cryopreservation, CBR believes in the power of newborn stem cells to improve lives today and their potential to revolutionize treatment for many conditions in the future.
Advancing Medicine
A pioneer in newborn stem cell collection and cryopreservation, CBR believes in the power of newborn stem cells to improve lives today and their potential to revolutionize treatment for many conditions in the future.
Cord Blood Registry (CBR) is the world’s largest newborn stem cell company. Founded in 1992, CBR is entrusted by parents with storing samples from more than 500,000 children. CBR is dedicated to advancing the clinical application of cord blood and cord tissue stem cells by partnering with institutions to establish FDA-regulated clinical trials for conditions that have no cure today.
CBR maintains standards for cellular therapy services through AABB accreditation, FDA-registration, and CLIA certification.
CBR has the longest history of accreditation with the AABB (formerly known as the American Association of Blood Banks) and the company’s quality standards have been recognized through ISO 9001:2008 certification — the global business standard for quality.
CBR maintains standards for cellular therapy services through AABB accreditation, FDA-registration, and CLIA certification.
CBR has the longest history of accreditation with the AABB (formerly known as the American Association of Blood Banks) and the company’s quality standards have been recognized through ISO 9001:2008 certification — the global business standard for quality.